BOSTON, Mass., September 15, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that senior management will participate in the UBS Biotechnology Private Company Virtual Symposium, being held September 21-22, 2022. For those attending the symposium, Dr. Anne Prener, president and chief executive officer, and Dr. Jai Patel, chief medical officer, will provide a corporate overview at 10:30am EDT on Thursday, September 22, 2022. Senior management will also participate in virtual one-on-one meetings with investors.